Metuchen Pharms Drug Patent Portfolio
Metuchen Pharms owns 1 orange book drug protected by 2 US patents Given below is the list of Metuchen Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds | 27 Apr, 2025 | Active |
| US7501409 | Preparations for oral administration | 05 May, 2023 | Expired |
Latest Legal Activities on Metuchen Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Metuchen Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Aug, 2020 | US7501409 (Litigated) |
|
Patent Term Extension Certificate
Critical
| 18 Mar, 2016 | US6656935 (Litigated) |
| Notice of Final Determination -Eligible | 18 Nov, 2015 | US6656935 (Litigated) |
|
FDA Final Eligibility Letter
Critical
| 21 Jan, 2015 | US6656935 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 10 Jun, 2014 | US6656935 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 09 May, 2014 | US6656935 (Litigated) |
| Second letter to regulating agency to determine regulatory review period | 19 Mar, 2014 | US6656935 (Litigated) |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Feb, 2013 | US6656935 (Litigated) |
| Initial letter Re: PTE Application to regulating agency | 28 Sep, 2012 | US6656935 (Litigated) |
| Patent Term Extension Application under 35 USC 156 Filed | 18 Jun, 2012 | US6656935 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 Mar, 2009 | US7501409 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 10 Mar, 2009 | US7501409 (Litigated) |
|
Email Notification
Critical
| 19 Feb, 2009 | US7501409 (Litigated) |
|
Issue Notification Mailed
Critical
| 18 Feb, 2009 | US7501409 (Litigated) |
|
Application Is Considered Ready for Issue
Critical
| 02 Feb, 2009 | US7501409 (Litigated) |
Metuchen Pharms's Family Patents
Metuchen Pharms drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 9.7% of its total global patent coverage. 19 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Metuchen Pharms Drug List
Given below is the complete list of Metuchen Pharms's drugs and the patents protecting them.
1. Stendra
Stendra is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds |
27 Apr, 2025
(6 months from now)
| Active |
| US7501409 | Preparations for oral administration |
05 May, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stendra's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List